Date: 2012-08-03
Type of information: Licensing agreement
Compound: Conformationally Restricted Nucleotide (CRN) technology for the development of both single- and double-stranded oligonucleotide therapeutic
Company: Novartis (Switzerland) Marina Biotech (USA)
Therapeutic area:
Type agreement: licensing
Action mechanism:
Disease:
Details: Marina Biotech, a nucleic acid-based drug discovery and development company, has entered into a licensing agreement with Novartis for Marina Biotech\'s Conformationally Restricted Nucleotide (CRN) technology for the development of both single- and double-stranded oligonucleotide therapeutics.
Marina Biotech is a biotechnology company focused on the development and commercialization of oligonucleotide-based therapeutics utilizing multiple mechanisms of action including RNA interference (RNAi) and messenger RNA translational blocking. The company has already entered into an exclusive agreement with The Debiopharm Group for the development and commercialization of the bladder cancer program (http://biopharmanalyses.fr/agreements/?pageid=623) . In addition, Marina Biotech has also entered into an agreement with both Mirna Therapeutics and ProNAi Therapeutics to license its SMARTICLES® technology for the delivery of microRNA mimics and DNAi, respectively.
Financial terms: Marina Biotech will receive $1 million in upfront fees for the non-exclusive license.
Latest news:
